696 Shares in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Purchased by New Age Alpha Advisors LLC

New Age Alpha Advisors LLC acquired a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 696 shares of the medical equipment provider’s stock, valued at approximately $79,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Accent Capital Management LLC acquired a new stake in Zimmer Biomet during the 1st quarter worth approximately $35,000. Raiffeisen Bank International AG increased its holdings in Zimmer Biomet by 34.4% during the first quarter. Raiffeisen Bank International AG now owns 16,659 shares of the medical equipment provider’s stock worth $1,870,000 after buying an additional 4,268 shares during the last quarter. Argent Trust Co increased its holdings in Zimmer Biomet by 11.2% during the first quarter. Argent Trust Co now owns 4,164 shares of the medical equipment provider’s stock worth $471,000 after buying an additional 419 shares during the last quarter. DCF Advisers LLC boosted its position in Zimmer Biomet by 17.5% during the first quarter. DCF Advisers LLC now owns 26,804 shares of the medical equipment provider’s stock worth $3,034,000 after purchasing an additional 3,985 shares during the period. Finally, Jefferies Financial Group Inc. boosted its position in Zimmer Biomet by 52.5% during the first quarter. Jefferies Financial Group Inc. now owns 28,487 shares of the medical equipment provider’s stock worth $3,224,000 after purchasing an additional 9,807 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of Zimmer Biomet stock opened at $99.95 on Tuesday. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. The company has a market cap of $19.80 billion, a PE ratio of 24.32, a P/E/G ratio of 2.28 and a beta of 0.68. The business has a 50 day moving average of $93.52 and a 200 day moving average of $99.57. Zimmer Biomet Holdings, Inc. has a 52 week low of $89.22 and a 52 week high of $116.71.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.98 by $0.09. The business had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%. The firm’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.01 earnings per share. As a group, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, July 31st. Investors of record on Thursday, June 26th were given a dividend of $0.24 per share. The ex-dividend date of this dividend was Thursday, June 26th. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is 23.36%.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 1,000 shares of the stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total value of $95,000.00. Following the transaction, the insider owned 20,424 shares of the company’s stock, valued at approximately $1,940,280. This represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.70% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ZBH. The Goldman Sachs Group reduced their target price on shares of Zimmer Biomet from $120.00 to $104.00 and set a “neutral” rating for the company in a research report on Tuesday, May 6th. Raymond James Financial boosted their target price on shares of Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a research report on Friday. Roth Capital reissued a “buy” rating on shares of Zimmer Biomet in a research report on Thursday. Canaccord Genuity Group reduced their target price on shares of Zimmer Biomet from $115.00 to $101.00 and set a “hold” rating for the company in a research report on Monday, May 12th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Zimmer Biomet from $128.00 to $105.00 and set an “overweight” rating for the company in a research report on Tuesday, May 6th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $111.44.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.